tada and fouremm thanks for the input.

I did see the 2% market share/penetration number and scratched my head. I remember quite a while back someone who has a clinical background did a post in which he/she said that if apabetalone achieved the BOM objectives it will probably become a SOC drug in every ER...it would be a necessary drug in the ER tool kit for it's particular indications. I do not know if this has merit or not but if there is some truth to it then the market penetration I would guess would be multiples larger than 2% I would guess.

Hartland, you made a very interesting point about Beacon covering primarily institutional investors if I understand this correctly. Does that not suggest some interesting possibilities? Of course they may still not come in at this stage.

Hope everybody has a great weekend.

Toinv